Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
2.
Neurocrit Care ; 24(1): 128-31, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26195088

ABSTRACT

BACKGROUND: Bowel ischemia is a rare life threatening complication seen in patients with refractory status epilepticus (RSE). The few reported cases of bowel ischemia in this setting have been associated with the use continuous barbiturate infusions. We report two patients with RSE in the absence of barbiturate infusion and without clear structural, infectious, anatomic, vascular, or autoimmune etiology. We review the clinical details of the cases and potential factors involved in the development of non-occlusive bowel ischemia in patients with RSE. METHODS: The following is a retrospective review of two cases of non-occlusive mesenteric ischemia that occurred during the management of RSE. The clinical data and the details of pathological examination of the infarcted segments of bowel are presented in both cases. RESULTS: In both cases, the bowel ischemia occurred in the absence of barbiturate infusion or evidence of clear thrombosis, infection, or autoimmune etiology. Case 1 had extensive ischemic necrosis of the small bowel with secondary pseudomembrane formation, and case 2 had full thickness infarction of both the large and small bowel. CONCLUSIONS: The mechanism of bowel infarction in these cases is likely multifactorial and was not associated with barbiturate use. Likely contributors to ischemia include RSE itself, systemic hypotension, vasopressor use, general anesthesia, and abnormal cardiac function. During the management of RSE, every effort must be made to avoid the secondary complications such as bowel ischemia.


Subject(s)
Mesenteric Ischemia/etiology , Status Epilepticus , Adult , Comorbidity , Female , Humans , Male , Mesenteric Ischemia/epidemiology , Middle Aged , Status Epilepticus/epidemiology , Young Adult
3.
Clin Exp Immunol ; 178(2): 292-309, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24965554

ABSTRACT

Sepsis is characterized by a severe systemic inflammatory response to infection that is associated with high morbidity and mortality despite optimal care. Invariant natural killer T (iNK T) cells are potent regulatory lymphocytes that can produce pro- and/or anti-inflammatory cytokines, thus shaping the course and nature of immune responses; however, little is known about their role in sepsis. We demonstrate here that patients with sepsis/severe sepsis have significantly elevated proportions of iNK T cells in their peripheral blood (as a percentage of their circulating T cells) compared to non-septic patients. We therefore investigated the role of iNK T cells in a mouse model of intra-abdominal sepsis (IAS). Our data show that iNK T cells are pathogenic in IAS, and that T helper type 2 (Th2) polarization of iNK T cells using the synthetic glycolipid OCH significantly reduces mortality from IAS. This reduction in mortality is associated with the systemic elevation of the anti-inflammatory cytokine interleukin (IL)-13 and reduction of several proinflammatory cytokines within the spleen, notably interleukin (IL)-17. Finally, we show that treatment of sepsis with OCH in mice is accompanied by significantly reduced apoptosis of splenic T and B lymphocytes and macrophages, but not natural killer cells. We propose that modulation of iNK T cell responses towards a Th2 phenotype may be an effective therapeutic strategy in early sepsis.


Subject(s)
Natural Killer T-Cells/immunology , Sepsis/immunology , Sepsis/pathology , Th2 Cells/immunology , Adult , Aged , Animals , Apoptosis/drug effects , Apoptosis/immunology , Cytokines/metabolism , Disease Models, Animal , Female , Glycolipids/administration & dosage , Glycolipids/pharmacology , Humans , Inflammation Mediators/metabolism , Lymphocyte Count , Male , Mice , Middle Aged , Natural Killer T-Cells/metabolism , Organ Specificity/immunology , Patient Outcome Assessment , Sepsis/drug therapy , Sepsis/mortality , Severity of Illness Index , Spleen/cytology , Spleen/drug effects , Spleen/immunology , Th2 Cells/metabolism
4.
Anal Chem ; 73(20): 4787-92, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11681452

ABSTRACT

Water in oil has been measured by tubular oven evaporation and by azeotropic distillation into a coulometric moisture analyzer. The results of these measurements were compared to the results obtained by volumetric titration of water in oil. The volumetric measurements were consistently higher than the measurements made by tubular oven evaporation or azeotropic distillation. A mass balance study was performed by volumetric Karl Fischer titration of the water in the oil that remained in the tubular oven and in the distillation apparatus. This study indicated that measurable amounts of water were not removed after exhaustive evaporation or distillation. The sum of the water removed by distillation from toluene and that remaining in the distillation chamber was equal to the amount of water measured in the oil by the volumetric method. The data are consistent with the existence of an oil-water azeotrope that does not release water upon evaporation at 160 degrees C or upon dissolution in toluene and distillation of the water-toluene azeotrope. These results were obtained for oils varying in viscosity from 8 to 850 m2/s, and the amount of water remaining associated with the oil appears to be dependent upon the composition of the oil and the method of analysis.

5.
Immunopharmacology ; 47(2-3): 215-45, 2000 May.
Article in English | MEDLINE | ID: mdl-10878291

ABSTRACT

With the development of new immunosuppressive agents, the focus of anti-rejection therapy has shifted from prevention of acute allograft rejection to an emphasis on sufficient immunosuppression with minimal toxicity. Mycophenolate mofetil (MMF) is a recently developed immunosuppressive drug, which acts to inhibit T and B cell proliferation by blocking the production of guanosine nucleotides required for DNA synthesis. It also prevents the glycosylation of adhesion molecules that are involved in attachment of lymphocytes to endothelium and potentially in leukocyte infiltration of an allograft during an immune response. High-quality randomized clinical trials have demonstrated that MMF, when used with cyclosporine (CsA) and steroids, reduces the frequency and severity of acute rejection episodes in kidney and heart transplants, improves patient and graft survival in heart allograft recipients and increases renal allograft survival at 3 years. It has also been effective in reversing acute and resistant rejection episodes in heart, kidney and liver recipients. The ability of MMF to facilitate sparing of other immunosuppressive agents, particularly in CsA-related nephrotoxicity, is also promising. By permitting reduction in CsA doses, MMF may stabilize or improve renal graft function in patients with CsA-related nephrotoxicity or chronic allograft nephropathy. Early results of phase I and II trials evaluating MMF therapy in liver and combined pancreas/kidney transplant recipients are encouraging. The main adverse effects associated with oral or intravenous MMF are gastrointestinal and hematologic in nature. Although the direct costs of using MMF vs. azathioprine (AZA) are higher, the decreased incidence and treatment of acute rejection in patients treated with MMF supports its use as a cost-effective option during the first year following transplantation.Thus, MMF has become an important therapeutic tool in the transplant clinician's armamentarium. Ongoing issues to be resolved in clinical trials include the role of MMF in the absence of other potent agents, e.g., as monotherapy or with a steroid but without calcineurin inhibitor; whether MMF will have an impact on chronic allograft dysfunction; and the cost-effectiveness of treatment following the first year of transplantation.


Subject(s)
Graft Rejection/drug therapy , Immunosuppressive Agents/therapeutic use , Mycophenolic Acid/analogs & derivatives , Animals , Humans , Mycophenolic Acid/metabolism , Mycophenolic Acid/pharmacology , Mycophenolic Acid/therapeutic use , Organ Transplantation , Purines/biosynthesis , Signal Transduction/drug effects , Signal Transduction/physiology , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism
6.
J Trauma ; 46(5): 847-52, 1999 May.
Article in English | MEDLINE | ID: mdl-10338402

ABSTRACT

BACKGROUND: The optimal method of evaluating blunt abdominal trauma remains controversial. A combination of a sensitive screening test, diagnostic peritoneal lavage (DPL), and a specific test, abdominal computed tomography (CT), may be a safe, efficient approach to adult blunt abdominal trauma. METHODS: A prospective cohort study compared a protocol using screening DPL followed by selective use of abdominal CT (DPL/abdominal CT) and the use of abdominal CT alone in the evaluation of hemodynamically stable, adult blunt trauma patients. RESULTS: One hundred sixty-seven adult blunt trauma patients were initially evaluated by DPL (n = 71) or abdominal CT (n = 96). Emergency department evaluation required less time in the DPL/abdominal CT group than in the abdominal CT alone group (41 minutes vs. 2.5 hours; p < 0.001). There were no missed injuries in the DPL/abdominal CT group versus seven missed injuries in the abdominal CT group (p = 0.02). There were no nontherapeutic celiotomies in either study group. CONCLUSION: Screening DPL, followed by abdominal CT if positive, is a safe, efficient method of evaluating adult blunt abdominal trauma that reduces the time required to evaluate the abdomen, does not result in increased nontherapeutic celiotomies, results in fewer missed injuries, and reduces the overall use of abdominal CT.


Subject(s)
Abdominal Injuries/diagnosis , Peritoneal Lavage , Tomography, X-Ray Computed , Wounds, Nonpenetrating/diagnosis , Abdominal Injuries/diagnostic imaging , Abdominal Injuries/therapy , Adult , Cohort Studies , Female , Humans , Male , Prospective Studies , Sensitivity and Specificity , Wounds, Nonpenetrating/diagnostic imaging , Wounds, Nonpenetrating/therapy
7.
J Pediatr Surg ; 31(7): 985-6, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8811576

ABSTRACT

Kawasaki disease is a syndrome characterized by multiple organ system inflammation and diffuse arteritis. Although gastrointestinal complications have been described, bowel obstruction rarely has been reported. The authors describe the case of a 1-year-old girl with Kawasaki disease who, after her acute illness, returned with mechanical bowel obstruction. During laparotomy, complete obstruction was found at the level of the jejunum, and resection was performed. Pathological examination of the resected specimen confirmed complete luminal obstruction with proliferation of granulation tissue, findings compatible with ischemic enteritis.


Subject(s)
Intestinal Obstruction/etiology , Jejunal Diseases/etiology , Mucocutaneous Lymph Node Syndrome/complications , Acute Disease , Arteritis/etiology , Enteritis/etiology , Enteritis/pathology , Female , Granulation Tissue/pathology , Humans , Infant , Intestinal Obstruction/pathology , Ischemia/etiology , Ischemia/pathology , Jejunal Diseases/pathology , Jejunum/blood supply , Laparotomy
SELECTION OF CITATIONS
SEARCH DETAIL
...